COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,891 Articles (22,568 medRxiv, 8,323 bioRxiv)

Most recent first Previous |  Page 2378: Articles 23771-23780  | Next

The potential health and economic impact of dexamethasone treatment for patients with COVID-19
AGUAS, R., Mahdi, A., SHRETTA, R., Horby, P., Landray, M., White, L. J.
10.1101/2020.07.29.20164269 — Posted: 2020-07-30
Brazilian dental students and COVID-19: a survey on knowledge and perceptions
Aragao, M. G. B., Fernandes Gomes, F. I., Pinho Maia Paixao de Melo, L., Milori Corona, S. A.
10.1101/2020.07.28.20163964 — Posted: 2020-07-30
Corticosteroid Use in Severely Hypoxemic COVID-19 Patients: An Observational Cohort Analysis of Dosing Patterns and Outcomes in the Early Phase of the Pandemic
Rahman, O., Trigonis, R. A., Craft, M. K., Kruer, R. M., Miller, E. M., Terry, C. L., Persaud, S. A., Kapoor, R.
10.1101/2020.07.29.20164277 — Posted: 2020-07-30
Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study.
Eimer, J., Vesterbacka, J., Svensson, A.-K., Stojanovic, B., Wagrell, C., Sonnerborg, A., Nowak, P.
10.1101/2020.07.29.20164160 — Posted: 2020-07-30
Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection
Townsend, L., Dyer, A. H., Jones, K., Dunne, J., Kiersey, R., Gaffney, F., O'Connor, L., Mooney, A., Leavy, D., Ridge, K., King, C., Cox, F., O'Brien, K., Dowds, J., Sugrue, J., Hopkins, D., Byrne, P., Kingston, T., Ni Cheallaigh, C., Nadarajan, P., McLaughlin, A. M., Bourke, N. M., Bergin, C., O'Farrelly, C., Bannan, C., Conlon, N.
10.1101/2020.07.29.20164293 — Posted: 2020-07-30 Discussion: Onsite
Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19
Chen, X., Pan, Z., Yue, S., Yu, F., Zhang, J., Yang, Y., Li, R., Liu, B., Yang, X., Gao, L., Li, Z., Lin, Y., Huang, Q., Xu, L., Tang, J., Hu, L., Zhao, J., Liu, P., Zhang, G., Chen, Y., Deng, K., Ye, L.
10.1101/2020.07.29.20164285 — Posted: 2020-07-30 Discussion: Onsite | Offsite
The genetic variants analysis of circulating SARS-CoV-2 in Bangladesh.
Mahmud, A. S. M., Taznin, T., Sarkar, M. M. H., Uzzaman, M. S., Osman, E., Habib, M. A., Akter, S., Banu, T. A., Goswami, B., Jahan, I., Hossain, M. S., Khan, M. S.
10.1101/2020.07.29.226555 — Posted: 2020-07-29 Discussion: Onsite
Impact Analysis of SARS-CoV2 on Signaling Pathways during COVID19 Pathogenesis using Codon Usage Assisted Host-Viral Protein Interactions
Das, J., Chakrobarty, S., Roy, S.
10.1101/2020.07.29.226217 — Posted: 2020-07-29
On the molecular mechanism of SARS-CoV-2 retention in the upper respiratory tract
Paris, K. A., Santiago, U., Camacho, C. J.
10.1101/2020.07.29.227389 — Posted: 2020-07-29
Genome-wide bioinformatic analyses predict key host and viral factors in SARS-CoV-2 pathogenesis
Ferrarini, M. G., Lal, A., Rebollo, R., Gruber, A., Guarracino, A., Martinez Gonzalez, I., Floyd, T., Siqueira de Oliveira, D., Shanklin, J., Beausoleil, E., Pusa, T., Pickett, B., Aguiar-Pulido, V.
10.1101/2020.07.28.225581 — Posted: 2020-07-29 Discussion: Offsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).